Pirfenidone for idiopathic pulmonary fibrosis

Lancet. 2011 May 21;377(9779):1727-9. doi: 10.1016/S0140-6736(11)60546-1. Epub 2011 May 13.

Author

Demosthenes Bouros¹

Affiliation

¹ Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, 68100 Greece. bouros@med.duth.gr

PMID: 21571363
DOI: 10.1016/S0140-6736(11)60546-1

No abstract available

Publication types

Comment

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Clinical Trials, Phase III as Topic
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Approval
Endpoint Determination
Europe
Evidence-Based Medicine
Exercise Test / drug effects
Humans
Idiopathic Pulmonary Fibrosis / drug therapy*
Pyridones / adverse effects
Pyridones / therapeutic use*
Randomized Controlled Trials as Topic
Vital Capacity / drug effects

Substances

Anti-Inflammatory Agents, Non-Steroidal
Pyridones
pirfenidone